NousCom CEO Outlines Cancer Vaccine Strategy
NousCom CEO and co-founder Alfredo Nicosia speaks to Scrip senior editor Lucie Ellis during BIO-Europe, a partnering meeting held in berlin Nov. 6-8, about the company's recent series B financing.
You may also be interested in...
John Beeler, vice-president of corporate and business development at Inivata, speaks to Scrip's Lucie Ellis about how the company's technology is aligned with the current genomic medicine revolution facing the pharmaceutical industry.
European biotech NousCom is making ready two multi-neoantigen containing vaccines that with a new round of VC funding should enter clinical studies in 2018, and that it hopes to combine with checkpoint inhibitors.
It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.